p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway

Fondevila, Marcos F.; Novoa, Eva; Gonzalez-Rellan, Maria J.; Fernandez, Uxia; Heras, Violeta; Porteiro, Begoña; Parracho, Tamara; Dorta, Valentina; Riobello, Cristina; da Silva Lima, Natalia; Seoane, Samuel; Garcia-Vence, Maria; Chantada-Vazquez, Maria P.; Bravo, Susana B.; Senra, Ana; Leiva, Magdalena; Marcos, Miguel; Sabio, Guadalupe; Perez-Fernandez, Roman; Dieguez, Carlos; Prevot, Vincent; Schwaninger, Markus; Woodhoo, Ashwin; Martinez-Chantar, Maria L.; Schwabe, Robert; Cubero, Francisco J.; Varela-Rey, Marta; Crespo, Javier; Iruzubieta, Paula; Nogueiras, Ruben

doi:10.1016/j.xcrm.2024.101401

Cited by 2 publications

(1 citation statement)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study showed that G proteincoupled receptor (GPCR) activation mediated PKM2 upregulation, which in turn enhanced glycolysis in Kupffer cells and suppressed hepatic inflammation, thereby alleviating highfat diet-induced obesity and MAFLD [109]. The activation of hepatic stellate cells (HSCs) is considered to be a key mechanism leading to liver fibrosis in MAFLD, and enhanced glycolysis contributes to HSCs activation and promotes the expression of fibrosis-related genes [110][111][112][113]. More importantly, over-enhanced glycolysis in hepatocytes predicts the tendency toward hepatocellular carcinoma, as tumor cells prefer to break down glucose into lactate via glycolysis to meet the energy demands for rapid proliferation, namely, the Warburg effect [114].…”

Section: Glycolysis and Mafldmentioning

confidence: 99%

Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective

Fu,

Wang,

Qin

2024

Metabolites

View full text Add to dashboard Cite

Metabolic-associated fatty liver disease (MAFLD), characterized primarily by hepatic steatosis, has become the most prevalent liver disease worldwide, affecting approximately two-fifths of the global population. The pathogenesis of MAFLD is extremely complex, and to date, there are no approved therapeutic drugs for clinical use. Considerable evidence indicates that various metabolic disorders play a pivotal role in the progression of MAFLD, including lipids, carbohydrates, amino acids, and micronutrients. In recent years, the medicinal properties of natural products have attracted widespread attention, and numerous studies have reported their efficacy in ameliorating metabolic disorders and subsequently alleviating MAFLD. This review aims to summarize the metabolic-associated pathological mechanisms of MAFLD, as well as the natural products that regulate metabolic pathways to alleviate MAFLD.

show abstract